About ADP-ribosylation factor-like protein 6-interacting protein 1
ADP-ribosylation factor-like protein 6-interacting protein 1 (ARL6IP1) is a protein
from Homo sapiens identified by UniProt accession
Q15041, 203 residues long.
MolForge cross-references it against 0 known binders and
46 disease associations.
Target properties
| Protein name | ADP-ribosylation factor-like protein 6-interacting protein 1 |
|---|
| UniProt accession | Q15041 |
|---|
| Gene | ARL6IP1 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 203 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (46)
Diseases linked to this target (Open Targets).
- hereditary spastic paraplegia 61 · score 0.67
- hereditary spastic paraplegia · score 0.61
- Autosomal recessive spastic paraplegia type 61 · score 0.55
- genetic disorder · score 0.18
- mean platelet volume · score 0.14
- heel bone mineral density · score 0.13
- HbA1c measurement · score 0.10
- Abnormality of refraction · score 0.06
- coffee consumption measurement · score 0.06
- tea consumption measurement · score 0.06
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q15041-F1 | alphafold | PREDICTED | 84.76 | — |
Amino-acid sequence (203 residues)
MAEGDNRSTN LLAAETASLE EQLQGWGEVM LMADKVLRWE RAWFPPAIMG VVSLVFLIIY YLDPSVLSGV SCFVMFLCLA DYLVPILAPR IFGSNKWTTE QQQRFHEICS NLVKTRRRAV GWWKRLFTLK EEKPKMYFMT MIVSLAAVAW VGQQVHNLLL TYLIVTSLLL LPGLNQHGII LKYIGMAKRE INKLLKQKEK KNE
Explore ADP-ribosylation factor-like protein 6-interacting protein 1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets